Consultation on the reimbursement status of medicinal products in ATC group A06 (laxatives) and A02AA04 (magnesium hydroxide)
At the Danish Medicines Agency’s request, the Reimbursement Committee has reassessed the reimbursement status of medicinal products authorised for marketing in Denmark in ATC group A06 (laxatives) and A02AA04 (magnesium hydroxide).
You may find a link to the Reimbursement Committee’s recommendation in the factbox to the right (in Danish only). The recommendation contains a list of links to the references which the Reimbursement Committee has emphasised in its recommendation.
On 28 April 2009, the Danish Medicines Agency initiated a consultation of the companies whose medicinal products are comprised by the Committee’s recommendations. A copy of the consultation letter can be downloaded from the factbox to the right (in Danish only).
The consultation deadline is Wednesday 27 May 2009.
Moreover, we have sent a notification about the Reimbursement Committee’s recommendation to the Danish Endocrine Society, Danish Society for Gastroenterology, Danish Gerontological Society, Danish Surgical Society, Danish Medical Society, Danish Paediatric Society, Danish College of General Practitioners, Danish Society of Geriatrics, Danish Association for the Study of the Liver, Danish Society of Internal Medicine, Danish Society for Clinical Nutrition and Metabolism, Danish Society of Clinical Pharmacology and Danish Society of Clinical Oncology. In addition, the National Board of Health and the Institute for Rational Pharmacotherapy have been briefed.
For further information, please contact the Reimbursement Department at email@example.com.
Danish Medicines Agency, 29 April 2009